Mammalian Transient Protein Expression Market Analysis

Global Mammalian Transient Protein Expression Market Definition

Mammalian transient protein expression is a method of protein expression where living organisms are used to develop a modified synthesis of proteins. This method of modified protein synthesis is complicated, delicate, and less productive compared to bacterial protein synthesis. The main advantage of mammalian transient protein expression is to develop a required translational modification with a natural structure. The new proteins are synthesized in the endoplasmic reticulum of mammalian cells.

Mammalian transient protein expression is a suitable expression of human or other mammalian proteins since it enables the quick production of protein in mammalians. This system has the capability to produce recombinant proteins such as glycosylation, along with post-translation modification and multiple native folds. Mammalian transient protein expression is required for structural, functional, and therapeutic studies since intracellular recombinant proteins can be easily generated, purified, and characterized from milligram to gram quantities.

Thermo fisher mammalian expression vector is also system that is utilized to reveal specialized fragment of DNA into mammalian systems for RNA. Mammalian expression vectors are based on mouse cell lines and human and considered to be more beneficial for the mammalian genes owing to cellular machinery similarity. The analysis of protein expression is conducted by the measurement of transcribed mRNA (northern blot).

Global Mammalian Transient Protein Expression Market: Key Insights

Base Year	2022
Forecast Year	2023-2033
CAGR	~8%
Base Year Market Size (2022)	~ USD 350 Million
Forecast Year Market Size (2033)	~ USD 650 Million
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Global Mammalian Transient Protein Expression Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global mammalian transient protein expression market is estimated to garner a revenue of ~USD 650 Million by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 350 Million in the year 2022. The growth of the market can be attributed primarily to the surging prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, kidney failure, and high blood pressure, rising demand for contamination-free and non-toxic methods, and the increasing adoption of antibodies for technological improvement in research activities. Furthermore, the transient protein in mammalian cells is used for the structural, therapeutic, and functional studies, and it is predicted to increase the market’s growth. As per the World Health Organization, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths.

Mammalian-Transient-Protein-Expression-Market-overview. Get more information on this report:Download Sample PDF

Mammalian cell lines are generally used to manufacture diverse immuno- and bio-therapeutic molecules. Key manufacturers are channelizing their efforts to increase the productivity, flexibility, and throughput capabilities as well as redefine control productivity of protein production using mammalian cell lines. The growing prevalence of communicable diseases such as polio, COVID-19, and chicken pox and the increase in the diagnostic population for variant diseases have propelled the overall demand for biological therapeutics, thus providing an opportunistic push to the growth of the global mammalian transient protein expression market. According to the estimations, more than 70% of the population worldwide is administered one dose, and over 60% of the population is administered two doses of the COVID-19 vaccine.

Global Mammalian Transient Protein Expression Market: Growth Drivers and Challenges

Growth Drivers

Increasing Geriatric Population Across the Globe to Trigger Reduction of Protein Synthesis – It was noticed the number and proportion of the geriatric population, meaning the people aged 60 years and older in the population was 1 billion in 2019 across the globe. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050.

The rise in the geriatric population all over the world, increasing incidences of chronic diseases, infections, and seasonal illnesses, and the increasing elderly population with the presence of various diseases are responsible for the market's development over the forecast period. The protein balance of the cells is disrupted as one grow older, and the proteostasis control system that regulates the maintenance and recycling of the proteome is damaged with age and becomes inefficient. This leads to improper function of the cell following age-related dysfunctions. The use of mammalian transient protein expression can improve protein synthesis.

Increasing Cases of Cancer Owing to Exposure to Harmful Carcinogens – The most recurrent cases of deaths as a result of cancer were lung cancer which caused 2.21 million deaths, colon and rectum cancer, which caused 1.93 million deaths, stomach cancer, which caused 1.09 million deaths, and breast cancer, which caused 2.26 million deaths in the year 2020 across the globe.
Prevalence of Cancer-Causing Diseases in Low and Lower-Middle-Income Nations – It was noticed that about 30% of cancer cases in low-and lower-middle-income nations are caused by cancer-causing diseases such as the human papillomavirus (HPV) and hepatitis.
Increasing Health Expenditure across the Global Population – As per the data by the World Bank, as of 2019, the global current health expenditure per capita was USD 1121.97.
Prevalence of STDs such as AIDS among the World Population – According to the World Health Organization (WHO), since the beginning of the HIV epidemic, about 84.2 million people worldwide have been infected and about 40.1 million have lost their life. Globally, 38.4 million people were living with HIV at the end of 2021.

Challenges

Lack of Expert Healthcare Professionals to Handle the Therapeutic Protein Generation - Mammalian transient protein expression is a rapid, cost-effective process, and on the other hand, it is a time-consuming generation that requires a highly skilled professional. Numerous samples have to be processed at the same time to benefit reproducibility. The shortage of experienced scientists is a limiting factor in market growth.
High Cost of Implementation in Equipment and Professionals
Risk of Contamination from Bacteria or Micro-Organisms

Global Mammalian Transient Protein Expression Market Segmentation

The global mammalian transient protein expression market is segmented and analyzed for demand and supply by end user into contract research organizations, biopharmaceutical companies, and academic & research institutes. Out of these types of segments, the contract research organizations segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the rising investments in R&D activities to continuously bring up more feasible solutions across the healthcare sector. According to research reports, global research and development spending has more than tripled in real terms since 2000, rising from approximately USD 680 billion to over USD 2.5 trillion in 2019. Besides, the increasing demand for biological products, including vaccines, antibodies, and therapeutic proteins, and growing investment in the drug development sector is further expected to drive the market’s growth.

The global mammalian transient protein expression market is also segmented and analyzed for demand and supply by application into bio-production, functional cell-based assays, academic research, and others. Amongst these segments, the bio-production segment is expected to garner a significant share. The growth of the segment can be ascribed to the higher demand for therapeutic proteins, coupled with the surging adoption of protein expression technology for the treatment of millions of patients. For instance, more than 95 genuine and modified therapeutic proteins are approved by the European Union for clinical use. Therapeutic proteins that are based on glycosylation are generally generated by the mammalian cell lines for biological activities.

Our in-depth analysis of the global mammalian transient protein expression market includes the following segments:

By Product	Instruments Expression Vector Reagents & Consumables Cell Lines
By Application	Bio-production Functional Cell-Based Assays Academic Research Others
By End User	Contract Research Organizations Biopharmaceutical Companies Academic & Research Institutes

Global Mammalian Transient Protein Expression Market Regional Synopsis

The North America mammalian transient protein expression market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the developing healthcare infrastructure, increasing government funds to support the health industry, the growing presence of prominent players, and rising healthcare expenditure. As of 2019, healthcare expenditures in the region accounted for 16.32% of the overall regional GDP. On the other hand, the surge in the cases of AIDS and STDs is also projected to expand the market size in the region during the forecast period. The prevalence of these diseases is observed to be higher in bisexuals, men who have sex with men (MSM), and others. For instance, the percentage of MSM and men who have sex with both men and women (MSMW) was projected to be around 45% in the regional population. Additionally, the number of people in the USA suffering from HIV reached approximately 35,000 in 2022. The market is further projected to grow on the back of escalating cases of various types of cancers in the region which is increasing the requirement for effective treatment along with efficient cancer services. Data released by the Centers for Disease Control and Prevention in 2029 showed that 599,589 people lost their lives while 1,752,735 new cases of cancer were diagnosed.

Mammalian-Transient-Protein-Expression-Market-regional Top Featured Companies Dominating the Global Mammalian Transient Protein Expression Market

Thermo Fisher Scientific company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Merck KGaA
Promega Corporation
Lonza Group
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
QIAGEN GmbH
Takara Bio India Pvt. Ltd.
HiMedia Laboratories Pvt Ltd
Sino Biological, Inc.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the mammalian transient protein expression market?

Ans: Increasing health expenditure across the global population are the major factors driving the market growth.

2) What would be the CAGR of mammalian transient protein expression market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 â€“ 2033.

3) What are the challenges affecting the mammalian transient protein expression market growth?

Ans: Lack of expert healthcare professionals to handle the therapeutic protein generation are estimated to be the growth hindering factors for the market expansion.

4) Which region will provide more business opportunities for growth of mammalian transient protein expression market in future?

Ans: The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

5) Who are the major players dominating the mammalian transient protein expression market?

Ans: The major players in the market are Merck KGaA, Promega Corporation, Lonza Group, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH, Takara Bio India Pvt. Ltd., HiMedia Laboratories Pvt. Ltd, Sino Biological, Inc., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the mammalian transient protein expression market?

Ans: The market is segmented by product, application, end-user, and by region.

8) Which segment captures the largest market size in the end user segment in the mammalian transient protein expression market?6) Which segment captures the largest market size in the end user segment in the mammalian transient protein expression market?

Ans: The contract research organizations segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.